Trovagene, Inc., a developer of cell-free molecular diagnostics, has entered into an agreement with America's Choice Provider Network (ACPN) establishing health insurance access to its entire suite of circulating tumor (ct) DNA Precision Cancer Monitoring (PCM) tests and services.

Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.

"We are very much looking forward to having a provider as progressive and innovative as Trovagene in our national provider network," said Seth Breeden, chief operating officer of ACPN. "It is with great excitement that we can now offer our members access to Trovagene's Precision Cancer Monitoring services."

"We are pleased that ACPN has agreed to provide coverage for Trovagene's PCM full offering of ctDNA products," said Matt Posard, chief commercial officer of Trovagene. "Our commercial plan is on track to provide national sales coverage, and ACPN is the first of several additional contracts expected this year. In support of our commercialization programme, we are creating a strong foundation of data from our clinical studies and manuscript publications demonstrating the medically actionable use of Trovagene's liquid biopsy platform in the treatment of cancer."

Founded in 2012, ACPN is an independent, multispecialty national provider network. Through its proprietary network and technology, ACPN offers access to providers, payers and patients in all 50 States, Canada, the Dominican Republic, Guam, Mexico, and Puerto Rico.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.